The identification of epidermal growth factor receptor (EGFR) mutations as a driver oncogene in non-small-cell lung cancer (NSCLC) and the efficacy of EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutated patients has revolutionized lung cancer treatment, with responses observed in 60–80% of patients [2,3,4,5,6,7,8,9,10]. The gene discussed is EGFR; the disease is lung cancer.